4 results
Comparison of steady-state cysteamine-trough WBC cystine levels between Cystagon® and RP103 over 3 months for each treatment period.
Primary objective: to investigate the safety of RFA in non-metastasized, irresectable locally advanced pancreatic cancer.Secondary objectives: to determine VAS pain score, length of hospital stay, survival, progression free survival and CA19-9…
- To assess the pharmacokinetic profile of cysteamine base after single dose administration of the new sustained-release cysteamine bitartrate (PO-001) to healthy volunteers, in comparison with Cystagon® and Procysbi®.- To collect safety/…
To confirm our previous findings that both TUS and auditory cuing decreases MEP amplitude in an independent sample using a more efficient design. Reducing the number of principal conditions will benefit data quality and allow for better estimation…